These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

327 related items for PubMed ID: 9175283

  • 21. Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555).
    George DJ, Dionne CA, Jani J, Angeles T, Murakata C, Lamb J, Isaacs JT.
    Cancer Res; 1999 May 15; 59(10):2395-401. PubMed ID: 10344749
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Complete androgen blockade for the treatment of prostate cancer.
    Labrie F, Dupont A, Belanger A.
    Important Adv Oncol; 1985 May 15; ():193-217. PubMed ID: 3916740
    [No Abstract] [Full Text] [Related]

  • 24. Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer.
    Miyake H, Hara I, Eto H.
    BJU Int; 2005 Oct 15; 96(6):791-5. PubMed ID: 16153202
    [Abstract] [Full Text] [Related]

  • 25. Intra-prostatic androgen levels during various androgen-blockade regimens.
    Nishiyama T.
    Best Pract Res Clin Endocrinol Metab; 2008 Apr 15; 22(2):229-41. PubMed ID: 18471782
    [Abstract] [Full Text] [Related]

  • 26. Combined androgen blockade: the gold standard for metastatic prostate cancer.
    McLeod DG, Crawford ED, DeAntoni EP.
    Eur Urol; 1997 Apr 15; 32 Suppl 3():70-7. PubMed ID: 9267789
    [Abstract] [Full Text] [Related]

  • 27. The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer.
    Cherrier MM, Rose AL, Higano C.
    J Urol; 2003 Nov 15; 170(5):1808-11. PubMed ID: 14532781
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. The change in the dihydrotestosterone level in the prostate before and after androgen deprivation therapy in connection with prostate cancer aggressiveness using the Gleason score.
    Nishiyama T, Ikarashi T, Hashimoto Y, Wako K, Takahashi K.
    J Urol; 2007 Oct 15; 178(4 Pt 1):1282-8; discussion 1288-9. PubMed ID: 17698092
    [Abstract] [Full Text] [Related]

  • 31. Anemia in patients on combined androgen block therapy for prostate cancer.
    Qian LX, Hua LX, Wu HF, Sui YG, Cheng SG, Zhang W, Li J, Wang XR.
    Asian J Androl; 2004 Dec 15; 6(4):383-4. PubMed ID: 15546035
    [Abstract] [Full Text] [Related]

  • 32. Overview of current status of total androgen deprivation in metastasized prostate cancer.
    Debruyne FM, Witjes WP.
    Eur Urol; 1993 Dec 15; 24 Suppl 2():67-71. PubMed ID: 8262129
    [Abstract] [Full Text] [Related]

  • 33. Overview of enzyme inhibitors and anti-androgens in prostatic cancer.
    Geller J.
    J Androl; 1991 Dec 15; 12(6):364-71. PubMed ID: 1769904
    [Abstract] [Full Text] [Related]

  • 34. Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer.
    Pummer K, Lehnert M, Stettner H, Hubmer G.
    Eur Urol; 1997 Dec 15; 32 Suppl 3():81-5. PubMed ID: 9267791
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. [First line therapy in the treatment of metastatic prostate cancer].
    Sakai H, Kanetake H.
    Gan To Kagaku Ryoho; 2003 Jan 15; 30(1):43-9. PubMed ID: 12557704
    [Abstract] [Full Text] [Related]

  • 37. Chlormadinone acetate withdrawal syndrome under combined androgen blockade for advanced prostate cancer.
    Sekido N, Kawai K, Akaza H, Koiso K.
    Jpn J Clin Oncol; 1995 Aug 15; 25(4):164-7. PubMed ID: 7545251
    [Abstract] [Full Text] [Related]

  • 38. Intermittent androgen suppression in prostate cancer: an update of the Vancouver experience.
    Pether M, Goldenberg SL, Bhagirath K, Gleave M.
    Can J Urol; 2003 Apr 15; 10(2):1809-14. PubMed ID: 12773232
    [Abstract] [Full Text] [Related]

  • 39. Androgen deprivation therapy for advanced prostate cancer: why does it fail and can its effects be prolonged?
    Singer EA, Golijanin DJ, Messing EM.
    Can J Urol; 2008 Dec 15; 15(6):4381-7. PubMed ID: 19046491
    [Abstract] [Full Text] [Related]

  • 40. Maximum vs. mono androgen blockade and the risk of recurrence in men with localized prostate cancer undergoing brachytherapy.
    Chen RC, Sadetsky N, Chen MH, Carroll PR, D'Amico AV.
    Int J Radiat Oncol Biol Phys; 2009 Sep 01; 75(1):36-9. PubMed ID: 19233568
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.